Reuters
24 Jul 2026, 13:45 UTC · 1h ago
Amgen submits new data to challenge FDA's proposal to withdraw Tavneos
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
24 Jul 2026, 13:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The FDA has proposed withdrawing Amgen's rare-disease drug Tavneos from the U.S. market. — The potential loss of a commercial product leads to immediate revenue loss and negative sentiment regarding the drug's viability.
-0.60Amgen submitted new evidence to the FDA on July 23 to challenge the proposed withdrawal and seek a hearing. — This represents a formal effort to preserve the asset, offering a potential path to avoid the withdrawal.
+0.30Which stocks this story touches
The company is fighting a proposed FDA withdrawal of its drug Tavneos from the U.S. market.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
